ES2247939B1 - FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. - Google Patents
FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. Download PDFInfo
- Publication number
- ES2247939B1 ES2247939B1 ES200402057A ES200402057A ES2247939B1 ES 2247939 B1 ES2247939 B1 ES 2247939B1 ES 200402057 A ES200402057 A ES 200402057A ES 200402057 A ES200402057 A ES 200402057A ES 2247939 B1 ES2247939 B1 ES 2247939B1
- Authority
- ES
- Spain
- Prior art keywords
- omega
- fatty acids
- treatment
- dha
- epa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A23L1/3006—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
Abstract
Suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica que consiste en la ingesta de un suplemento diario de ácidos grasos Omega-3 durante seis meses en forma oleoil o cápsulas blandas distribuido en las tres principales comidas diarias.Food supplement based on the use of Omega-3 fatty acids (DHA and EPA) for the treatment of chronic fatigue syndrome consisting of the intake of a daily supplement of Omega-3 fatty acids for six months in oleoyl form or distributed soft capsules in the three main daily meals.
Description
Suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica.Food supplement based on utilization of Omega-3 fatty acids (DHA and EPA) for Treatment of chronic fatigue syndrome.
La presente memoria descriptiva se refiere a una solicitud de una Patente de Invención correspondiente a un suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica que consiste en que la administración de un suplemento dietético de AG3 en pacientes con síndrome de fatiga crónica, permitiendo la mejoría de parámetros biológicos y clínicos característicos de la enfermedad.The present specification refers to a request for an Invention Patent corresponding to a nutritional supplement based on the use of fatty acids Omega-3 (DHA and EPA) for the treatment of chronic fatigue syndrome which is that the administration of a dietary supplement of AG3 in patients with fatigue syndrome chronic, allowing the improvement of biological and clinical parameters characteristic of the disease.
Esta invención tiene su aplicación dentro de la industria dedicada a la fabricación de medicamentos y en general en el campo de la medicina.This invention has its application within the industry dedicated to the manufacture of medicines and in general in The medical field.
El síndrome de fatiga crónica (SFC) cuyo acrónimo en inglés es CFS, está reconocido como una enfermedad sistémica severa que se caracteriza por fatiga extrema, física y mental junto a otros síntomas que afectan a los sistemas inmunológico, endocrinológico y neurológico, fundamentalmente.Chronic fatigue syndrome (CFS) whose Acronym in English is CFS, it is recognized as a disease severe systemic characterized by extreme fatigue, physical and mental along with other symptoms that affect the systems Immune, endocrinological and neurological, fundamentally.
El diagnóstico de la enfermedad se basa en la aplicación de unos criterios internacionalmente aceptados (conocidos como de Fukuda o del CDC).The diagnosis of the disease is based on the application of internationally accepted criteria (known as Fukuda or CDC).
Si bien al principio se pensó que se trataba de la secuela de una enfermedad viral aguda, actualmente se hipotiza al respecto de una patogenia multifactorial en la que pueden tener gran valor las reactivaciones de virus latentes y otros microorganismos, predominantemente intracelulares.While at first it was thought that it was about the aftermath of an acute viral disease, is currently hypotized about a multifactor pathogenesis in which they can have great value the reactivations of latent and other viruses microorganisms, predominantly intracellular.
La relación de síntomas y signos de tipo neuro-inmune-endocrinológico del síndrome sería exhaustiva, pero algunos de ellos se repiten de forma estadísticamente significativa en muchos afectados, de forma que adquieren un especial valor.The relationship of symptoms and type signs neuro-immune-endocrinological syndrome would be exhaustive, but some of them recur from statistically significant in many affected, so They acquire a special value.
Por el momento, no existe un tratamiento causal de la enfermedad y se buscan métodos y técnicas que permitan la clasificación de la gravedad de la fatiga (y de la enfermedad en general) y que puedan orientar un pronóstico de la misma y una expectativa de tratamiento enfocado a las moléculas diana (especialmente implicadas) de la enfermedad.At the moment, there is no causal treatment of the disease and methods and techniques that allow the classification of the severity of fatigue (and of the disease in general) and that can guide a forecast of it and a treatment expectation focused on the target molecules (especially involved) of the disease.
Entre otras muchas, se ha constatado una disminución de la proporción de ácidos grasos, en concreto del Ácido Giberélico (AG3) de la familia de los llamados Omega-3, en la membrana del hematíe.Among many others, a decrease in the proportion of fatty acids, specifically Gibberellic Acid (AG3) of the so-called family Omega-3, in the red blood cell membrane.
Este ácido graso, presente en muchas otras estructuras de la economía corporal (sobre todo membranas neurales), desempeña importantes papeles y puede explicar muchos síntomas típicos del síndrome de fatiga crónica y permitiendo una vía de tratamiento eficaz.This fatty acid, present in many others body economy structures (especially membranes neural), plays important roles and can explain many typical symptoms of chronic fatigue syndrome and allowing a Effective treatment route.
El suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica que la invención propone, mejora de forma sustancial la calidad de vida de los enfermos sometidos a su tratamiento.The nutritional supplement based on the use of Omega-3 fatty acids (DHA and EPA) for the treatment of chronic fatigue syndrome that the invention proposes, substantially improves the quality of life of Patients undergoing treatment.
De forma más concreta, el suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica objeto de la invención, está constituido a partir de la selección de un grupo de pacientes con síndrome de fatiga crónica, diagnosticados según los citados criterios internacionales, descartándose de presión mayor mediante la aplicación de la MINI- Entrevista Neuropsiquiátrica Internacional.More specifically, the supplement food based on the use of fatty acids Omega-3 (DHA and EPA) for the treatment of the syndrome of chronic fatigue object of the invention, is constituted to from the selection of a group of patients with syndrome chronic fatigue, diagnosed according to the aforementioned criteria international, discarding greater pressure through the MINI application - Neuropsychiatric Interview International.
El protocolo del trabajo y el objetivo, consistía en comprobar si la suplementación dietética del ácido graso AG3 podía mejorar la funcionalidad física y psicológica de los pacientes y verificar si esta mejoría se contrastaba con variación de parámetros analíticos, como por ejemplo la actividad de la vía 2-50AS, PKR, elastasas, neopterina y escalas de valoración neurocognitiva y función física.The work protocol and the objective, was to check if dietary acid supplementation fatty AG3 could improve the physical and psychological functionality of patients and verify if this improvement was contrasted with variation of analytical parameters, such as activity of the 2-50AS, PKR, elastase, neopterin and Neurocognitive assessment scales and physical function.
Como quiera que se aplica un protocolo que aborda varias especialidades, el estudio se diseñó también para evaluar el consumo de oxígeno frente al esfuerzo (con equipos configurados como el de la banda rodante, la bicicleta de esfuerzo o con equipos de valoración segmentaria de brazos y piernas), relacionando el consumo de oxígeno con la IGF-1 y otras valoraciones hormonales (Cortisol en sangre y Orina, ACTH, Prolactina, Testosterona, Estrógenos e IGF-1 y si procedía, test de secreción de GH tras estimulación) y enzimáticas (ATPasa).However a protocol is applied that addresses several specialties, the study was also designed to evaluate oxygen consumption versus effort (with equipment configured as the treadmill, the exercise bike or with segmental assessment equipment of arms and legs), relating oxygen consumption with IGF-1 and Other hormonal assessments (Cortisol in blood and urine, ACTH, Prolactin, Testosterone, Estrogens and IGF-1 and yes proceeded, GH secretion test after stimulation) and enzymatic (ATPase).
Para la valoración se utilizó la escala de impacto de fatiga, el SF-36, Actimetría mediante Actímetros y la batería neuropsicológica Luria Nebraska (WPS-000).For the assessment, the scale of fatigue impact, the SF-36, Actimetry through Actimeters and the neuropsychological battery Luria Nebraska (WPS-000).
Se determinaron ácidos grasos en plasma y en membrana eritrocitaria, antes, durante y después del estudio.Fatty acids were determined in plasma and in erythrocyte membrane, before, during and after the study.
Los pacientes tomaron un suplemento diario de ácidos grasos Omega-3 consistente en 1 gr./día de ácido graso poliinsaturado docosahexaenoico (DHA) y 1 gr./día de Ácido Eicosapentanoico (EPA) distribuido en las tres principales comidas diarias y preparado en forma oleoil, aunque podría suministrarse en otras formulaciones.The patients took a daily supplement of Omega-3 fatty acids consisting of 1 gr./day of docosahexaenoic polyunsaturated fatty acid (DHA) and 1 gr./day of Eicosapentanoic Acid (EPA) distributed in the three main daily meals and prepared in oil form, although it could be supplied in other formulations.
Los pacientes tomaron esta suplementación durante seis meses y fueron evaluados antes, durante y después (tres meses después) del tratamiento.The patients took this supplementation for six months and were evaluated before, during and after (three months later) of the treatment.
El tratamiento estadístico de los datos evidenció una mejoría significativa tanto en los parámetros físicos como neuropsicológicos, verificándose la hipótesis de normalidad de la muestra.The statistical treatment of the data evidenced a significant improvement in both physical parameters as neuropsychological, verifying the hypothesis of normality of the sample.
El suplemento alimenticio basado en la utilización de ácidos grasos Omega-3 (DHA y EPA) para el tratamiento del síndrome de fatiga crónica que la invención propone, está constituido a partir de la ingesta de un suplemento diario de ácidos grasos de Omega-3 consiste en un gramo al día de ácido graso poliinsaturado docosahexaenoico (DHA) y 1 gramo diario de Ácido Eicosapentanoico (EPA) distribuido en las tres principales comidas diarias y preparado en forma oleoil, o cápsula blanda, aunque podría suministrarse en otras formulaciones.The nutritional supplement based on the use of Omega-3 fatty acids (DHA and EPA) for the treatment of chronic fatigue syndrome that the invention proposes, it is constituted from the intake of a Omega-3 daily fatty acid supplement It consists of one gram per day of polyunsaturated fatty acid docosahexaenoic acid (DHA) and 1 gram daily of Eicosapentanoic Acid (EPA) distributed in the three main daily meals and prepared in oil form, or soft capsule, although it could be supplied in other formulations.
La ingesta se realiza durante seis meses.The intake is done for six months.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200402057A ES2247939B1 (en) | 2004-08-19 | 2004-08-19 | FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200402057A ES2247939B1 (en) | 2004-08-19 | 2004-08-19 | FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2247939A1 ES2247939A1 (en) | 2006-03-01 |
| ES2247939B1 true ES2247939B1 (en) | 2007-04-01 |
Family
ID=35986448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200402057A Expired - Fee Related ES2247939B1 (en) | 2004-08-19 | 2004-08-19 | FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2247939B1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
| JP2004531568A (en) * | 2001-05-30 | 2004-10-14 | ラクスデイル リミテッド | Coenzyme Q and eicosapentaenoic acid (EPA) |
-
2004
- 2004-08-19 ES ES200402057A patent/ES2247939B1/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| BEHAN, P.O. et al. "Effect of high doses of essential fatty acids on the postviral fatigue syndrome". Acta Neurologica Scandinavica. 1990. Vol. 82, nº 3, páginas 209-216. * |
| LIU, Z. et al. "Determination of Fatty Acid Levels in Erytrocyte Membranes of Patients with Chronic Fatigue Syndrome". Nutritional Neuroscience. 2003. Vol. 6, nº 6, páginas 389-392. * |
| PURI, B.K. "The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome". Prostaglandins, leukotrienes, and essential fatty acids. Abril 2004. Vol. 70, nº 4, páginas 399-401. * |
| PURI, B.K. et al. "Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symtom remission and structural brain changes". International Journal of Clinical Practice. Marzo 2004. Vol. 58, nº 3, páginas 297-299. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2247939A1 (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Toups et al. | Precision medicine approach to Alzheimer’s disease: Successful pilot project | |
| El-Bahr et al. | Trypanosoma evansi in naturally infected dromedary camels: lipid profile, oxidative stress parameters, acute phase proteins and proinflammatory cytokines | |
| Szczeklik et al. | Alterations in glutathione peroxidase and superoxide dismutase activities in plasma and saliva in relation to disease activity in patients with Crohn’s disease | |
| Ahmad et al. | Upregulation of interleukin (IL)-31, a cytokine producing CXCR1 peripheral immune cells, contributes to the immune abnormalities of autism spectrum disorder | |
| JP2011256145A (en) | Medical composition for treatment and prophylaxis of disease associated with th3 march | |
| Han et al. | Lymphocyte subset alterations related to executive function deficits and repetitive stereotyped behavior in autism | |
| ES2247939B1 (en) | FOOD SUPPLEMENT BASED ON THE USE OF OMEGA-3 FATTY ACIDS (DHA-EPA) FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME. | |
| Dulman et al. | Variations in standard blood count and biochemical parameters in dogs with atopic dermatitis. | |
| Nazni et al. | Impact of casein and gluten free dietary intervention on selected autistic children | |
| ES2395686T5 (en) | Vitamin E supplement to boost the immune response to tetanus toxoid | |
| RU2339043C1 (en) | Method of diagnostics of consequences of perinayal lesions of central nervous system of small degree at children | |
| North | Discovering links between inflammation, neurogenesis, brain structure and brain function in schizophrenia | |
| Denman | Food allergy | |
| Ueland et al. | Total homocysteine is making its way into pediatric laboratory diagnostics | |
| Lim et al. | Ingestion of exopolymers from aureobasidium pullulans reduces the duration of cold and flu symptoms: a randomized, placebo-controlled intervention study | |
| Hamadneh et al. | Nutritional and Dietary Interventions of Autistic Spectrum Disorders: A Short Review | |
| MAILIZA | Diagnosis and management chronic anemia in herpes simplex virus (HSV) type 1 infection | |
| Nura Nasibe et al. | Amino acids profile in mentally retarded Libyan children | |
| Frățilă et al. | ALZHEIMER'S DEMENTIA AND PERIODONTAL DISEASE: A DOUBLE-EDGED SWORD | |
| Hoq | Short-term effects of repeated neonatal oral sucrose treatment and pain on hippocampal and serum inflammatory cytokine levels and microglia density in mouse pups | |
| Çadırcı et al. | A case of brucellosis with severe thrombocytopenia | |
| Biyani et al. | Citrullinemia type 1: a rare case | |
| Mian et al. | contacting Dr. Deepak Kamat at dkamat@ med. wayne. edu. | |
| Vedpathak et al. | Clinical and ferroscopic studies on foreign body syndrome in cattle | |
| LINNELL et al. | RETRACTED: Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis, and Pervasive Developmental Disorder in Children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20060301 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2247939B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180809 |